메뉴 건너뛰기




Volumn 30, Issue 25, 2012, Pages 3109-3118

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures

(22)  Mendler, Jason H a   Maharry, Kati a,b   Radmacher, Michael D a,b   Mrózek, Krzysztof a   Becker, Heiko a   Metzeler, Klaus H a   Schwind, Sebastian a   Whitman, Susan P a   Khalife, Jihane a   Kohlschmidt, Jessica a,b   Nicolet, Deedra a,b   Powell, Bayard L c   Carter, Thomas H e   Wetzler, Meir f   Moore, Joseph O d   Kolitz, Jonathan E g   Baer, Maria R h   Carroll, Andrew J i   Larson, Richard A j   Caligiuri, Michael A a   more..


Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CADMIUM 109; CD135 ANTIGEN; CYTARABINE; DNA NUCLEOTIDYLEXOTRANSFERASE; FLT3 LIGAND; MICRORNA; MICRORNA 223; TRANSCRIPTION FACTOR RUNX1;

EID: 84865720625     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.6652     Document Type: Article
Times cited : (223)

References (56)
  • 1
    • 48749123878 scopus 로고    scopus 로고
    • Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics
    • Gaidzik V, Döhner K: Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35:346-355, 2008
    • (2008) Semin Oncol , vol.35 , pp. 346-355
    • Gaidzik, V.1    Döhner, K.2
  • 3
    • 33846230449 scopus 로고    scopus 로고
    • Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification?
    • Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007
    • (2007) Blood , vol.109 , pp. 431-448
    • Mrózek, K.1    Marcucci, G.2    Paschka, P.3
  • 4
    • 0037097716 scopus 로고    scopus 로고
    • Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
    • Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
    • (2002) Blood , vol.99 , pp. 4326-4335
    • Thiede, C.1    Steudel, C.2    Mohr, B.3
  • 5
    • 0035476264 scopus 로고    scopus 로고
    • Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study
    • Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 61:7233-7239, 2001
    • (2001) Cancer Res , vol.61 , pp. 7233-7239
    • Whitman, S.P.1    Archer, K.J.2    Feng, L.3
  • 6
    • 28444473100 scopus 로고    scopus 로고
    • Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations
    • Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
    • (2005) Blood , vol.106 , pp. 3740-3746
    • Döhner, K.1    Schlenk, R.F.2    Habdank, M.3
  • 7
    • 19944427850 scopus 로고    scopus 로고
    • Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
    • Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005
    • (2005) N Engl J Med , vol.352 , pp. 254-266
    • Falini, B.1    Mecucci, C.2    Tiacci, E.3
  • 8
    • 1442356729 scopus 로고    scopus 로고
    • CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations
    • Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 624-633
    • Fröhling, S.1    Schlenk, R.F.2    Stolze, I.3
  • 9
    • 55549103713 scopus 로고    scopus 로고
    • Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study
    • Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 5078-5087
    • Marcucci, G.1    Maharry, K.2    Radmacher, M.D.3
  • 10
    • 53749101166 scopus 로고    scopus 로고
    • Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 26:4595-4602, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 4595-4602
    • Paschka, P.1    Marcucci, G.2    Ruppert, A.S.3
  • 11
    • 56749098118 scopus 로고    scopus 로고
    • Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
    • Virappane P, Gale R, Hills R, et al: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-5435, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 5429-5435
    • Virappane, P.1    Gale, R.2    Hills, R.3
  • 12
    • 0031984414 scopus 로고    scopus 로고
    • Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics
    • Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59, 1998
    • (1998) Cancer Res , vol.58 , pp. 55-59
    • Caligiuri, M.A.1    Strout, M.P.2    Lawrence, D.3
  • 13
    • 34250011216 scopus 로고    scopus 로고
    • Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study
    • Whitman SP, Ruppert AS, Marcucci G, et al: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 109:5164-5167, 2007
    • (2007) Blood , vol.109 , pp. 5164-5167
    • Whitman, S.P.1    Ruppert, A.S.2    Marcucci, G.3
  • 14
    • 77952536841 scopus 로고    scopus 로고
    • IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 2348-2355
    • Marcucci, G.1    Maharry, K.2    Wu, Y.Z.3
  • 15
    • 77955907891 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
    • Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3636-3643
    • Paschka, P.1    Schlenk, R.F.2    Gaidzik, V.I.3
  • 16
    • 79954428737 scopus 로고    scopus 로고
    • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 1373-1381
    • Metzeler, K.H.1    Maharry, K.2    Radmacher, M.D.3
  • 17
    • 77449159028 scopus 로고    scopus 로고
    • Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
    • Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
    • (2010) Blood , vol.115 , pp. 453-474
    • Döhner, H.1    Estey, E.H.2    Amadori, S.3
  • 18
    • 77449140390 scopus 로고    scopus 로고
    • Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study
    • Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 596-604
    • Becker, H.1    Marcucci, G.2    Maharry, K.3
  • 19
    • 0030061554 scopus 로고    scopus 로고
    • AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
    • Okuda T, van Deursen J, Hiebert SW, et al: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330, 1996
    • (1996) Cell , vol.84 , pp. 321-330
    • Okuda, T.1    Van Deursen, J.2    Hiebert, S.W.3
  • 20
    • 0037082499 scopus 로고    scopus 로고
    • In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis
    • Michaud J, Wu F, Osato M, et al: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 99:1364-1372, 2002
    • (2002) Blood , vol.99 , pp. 1364-1372
    • Michaud, J.1    Wu, F.2    Osato, M.3
  • 21
    • 0032830638 scopus 로고    scopus 로고
    • Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
    • Song WJ, Sullivan MG, Legare RD, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175, 1999
    • (1999) Nat Genet , vol.23 , pp. 166-175
    • Song, W.J.1    Sullivan, M.G.2    Legare, R.D.3
  • 22
    • 1542373639 scopus 로고    scopus 로고
    • High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia
    • Harada H, Harada Y, Niimi H, et al: High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103:2316-2324, 2004
    • (2004) Blood , vol.103 , pp. 2316-2324
    • Harada, H.1    Harada, Y.2    Niimi, H.3
  • 23
    • 34848824979 scopus 로고    scopus 로고
    • RUNX1 gene mutation in primary myelodysplastic syndrome: The mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
    • Chen CY, Lin LI, Tang JL, et al: RUNX1 gene mutation in primary myelodysplastic syndrome: The mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 139:405-414, 2007
    • (2007) Br J Haematol , vol.139 , pp. 405-414
    • Chen, C.Y.1    Lin, L.I.2    Tang, J.L.3
  • 24
    • 0034667690 scopus 로고    scopus 로고
    • High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21
    • Preudhomme C, Warot-Loze D, Roumier C, et al: High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96:2862-2869, 2000
    • (2000) Blood , vol.96 , pp. 2862-2869
    • Preudhomme, C.1    Warot-Loze, D.2    Roumier, C.3
  • 25
    • 0037441589 scopus 로고    scopus 로고
    • M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: A report of 59 cases by the Groupe Français d'Hé matologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)
    • Roumier C, Eclache V, Imbert M, et al: M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: A report of 59 cases by the Groupe Français d'Hé matologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). Blood 101:1277-1283, 2003
    • (2003) Blood , vol.101 , pp. 1277-1283
    • Roumier, C.1    Eclache, V.2    Imbert, M.3
  • 26
    • 9144270483 scopus 로고    scopus 로고
    • Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype
    • Matsuno N, Osato M, Yamashita N, et al: Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. Leukemia 17:2492-2499, 2003
    • (2003) Leukemia , vol.17 , pp. 2492-2499
    • Matsuno, N.1    Osato, M.2    Yamashita, N.3
  • 27
    • 0037473113 scopus 로고    scopus 로고
    • Identification of RUNX1/AML1 as a classical tumor suppressor gene
    • Silva FP, Morolli B, Storlazzi CT, et al: Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 22:538-547, 2003
    • (2003) Oncogene , vol.22 , pp. 538-547
    • Silva, F.P.1    Morolli, B.2    Storlazzi, C.T.3
  • 28
    • 35748939738 scopus 로고    scopus 로고
    • Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients
    • Silva FP, Lind A, Brouwer-Mandema G, et al: Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 92:1123-1126, 2007
    • (2007) Haematologica , vol.92 , pp. 1123-1126
    • Silva, F.P.1    Lind, A.2    Brouwer-Mandema, G.3
  • 29
    • 34548044732 scopus 로고    scopus 로고
    • Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia
    • Dicker F, Haferlach C, Kern W, et al: Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 110:1308-1316, 2007
    • (2007) Blood , vol.110 , pp. 1308-1316
    • Dicker, F.1    Haferlach, C.2    Kern, W.3
  • 30
    • 0033559746 scopus 로고    scopus 로고
    • Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias
    • Osato M, Asou N, Abdalla E, et al: Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 93:1817-1824, 1999
    • (1999) Blood , vol.93 , pp. 1817-1824
    • Osato, M.1    Asou, N.2    Abdalla, E.3
  • 31
    • 79952134550 scopus 로고    scopus 로고
    • RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
    • Schnittger S, Dicker F, Kern W, et al: RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 117:2348-2357, 2011
    • (2011) Blood , vol.117 , pp. 2348-2357
    • Schnittger, S.1    Dicker, F.2    Kern, W.3
  • 32
    • 79954448043 scopus 로고    scopus 로고
    • RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML Study Group
    • Gaidzik VI, Bullinger L, Schlenk RF, et al: RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol 29:1364-1372, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 1364-1372
    • Gaidzik, V.I.1    Bullinger, L.2    Schlenk, R.F.3
  • 33
    • 73949090504 scopus 로고    scopus 로고
    • AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations
    • Tang JL, Hou HA, Chen CY, et al: AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 114:5352-5361, 2009
    • (2009) Blood , vol.114 , pp. 5352-5361
    • Tang, J.L.1    Hou, H.A.2    Chen, C.Y.3
  • 34
    • 0036009568 scopus 로고    scopus 로고
    • Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7
    • Langabeer SE, Gale RE, Rollinson SJ, et al: Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer 34:24-32, 2002
    • (2002) Genes Chromosomes Cancer , vol.34 , pp. 24-32
    • Langabeer, S.E.1    Gale, R.E.2    Rollinson, S.J.3
  • 35
    • 48749119622 scopus 로고    scopus 로고
    • Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience
    • Mrózek K, Carroll AJ, Maharry K, et al: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 33:239-244, 2008
    • (2008) Int J Oncol , vol.33 , pp. 239-244
    • Mrózek, K.1    Carroll, A.J.2    Maharry, K.3
  • 36
    • 38949212204 scopus 로고    scopus 로고
    • FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    • Whitman SP, Ruppert AS, Radmacher MD, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559, 2008
    • (2008) Blood , vol.111 , pp. 1552-1559
    • Whitman, S.P.1    Ruppert, A.S.2    Radmacher, M.D.3
  • 37
    • 13344249756 scopus 로고    scopus 로고
    • Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11
    • Caligiuri MA, Strout MP, Schichman SA, et al: Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56:1418-1425, 1996
    • (1996) Cancer Res , vol.56 , pp. 1418-1425
    • Caligiuri, M.A.1    Strout, M.P.2    Schichman, S.A.3
  • 38
    • 84255176496 scopus 로고    scopus 로고
    • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
    • Metzeler KH, Becker H, Maharry K, et al: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:6920-6929, 2011
    • (2011) Blood , vol.118 , pp. 6920-6929
    • Metzeler, K.H.1    Becker, H.2    Maharry, K.3
  • 39
    • 84863116398 scopus 로고    scopus 로고
    • Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
    • Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:742-750, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 742-750
    • Marcucci, G.1    Metzeler, K.H.2    Schwind, S.3
  • 40
    • 80051663269 scopus 로고    scopus 로고
    • Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder
    • (abstr 2709)
    • Garcia JS, Madzo J, Cooper D, et al: Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder. Blood 116:1116-1117, 2010 (abstr 2709)
    • (2010) Blood , vol.116 , pp. 1116-1117
    • Garcia, J.S.1    Madzo, J.2    Cooper, D.3
  • 41
    • 3042820902 scopus 로고    scopus 로고
    • Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells
    • Georgantas RW 3rd, Tanadve V, Malehorn M, et al: Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 64:4434-4441, 2004
    • (2004) Cancer Res , vol.64 , pp. 4434-4441
    • Georgantas III, R.W.1    Tanadve, V.2    Malehorn, M.3
  • 42
    • 18744386948 scopus 로고    scopus 로고
    • Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells
    • He X, Gonzalez V, Tsang A, et al: Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells. Stem Cells Dev 14:188-198, 2005
    • (2005) Stem Cells Dev , vol.14 , pp. 188-198
    • He, X.1    Gonzalez, V.2    Tsang, A.3
  • 43
    • 0032803285 scopus 로고    scopus 로고
    • CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells
    • Murray LJ, Bruno E, Uchida N, et al: CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27:1282-1294, 1999
    • (1999) Exp Hematol , vol.27 , pp. 1282-1294
    • Murray, L.J.1    Bruno, E.2    Uchida, N.3
  • 44
    • 25444452414 scopus 로고    scopus 로고
    • CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia
    • Toren A, Bielorai B, Jacob-Hirsch J, et al: CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23:1142-1153, 2005
    • (2005) Stem Cells , vol.23 , pp. 1142-1153
    • Toren, A.1    Bielorai, B.2    Jacob-Hirsch, J.3
  • 45
    • 80052468964 scopus 로고    scopus 로고
    • Stem cell gene expression programs influence clinical outcome in human leukemia
    • Eppert K, Takenaka K, Lechman ER, et al: Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086-1093, 2011
    • (2011) Nat Med , vol.17 , pp. 1086-1093
    • Eppert, K.1    Takenaka, K.2    Lechman, E.R.3
  • 46
    • 78650444882 scopus 로고    scopus 로고
    • Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
    • Gentles AJ, Plevritis SK, Majeti R, et al: Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304:2706-2715, 2010
    • (2010) JAMA , vol.304 , pp. 2706-2715
    • Gentles, A.J.1    Plevritis, S.K.2    Majeti, R.3
  • 47
    • 79953070487 scopus 로고    scopus 로고
    • Molecular resolution of the B cell landscape
    • Santos PM, Borghesi L: Molecular resolution of the B cell landscape. Curr Opin Immunol 23:163-170, 2011
    • (2011) Curr Opin Immunol , vol.23 , pp. 163-170
    • Santos, P.M.1    Borghesi, L.2
  • 48
    • 0041440085 scopus 로고    scopus 로고
    • BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study
    • Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 102:1613-1618, 2003
    • (2003) Blood , vol.102 , pp. 1613-1618
    • Baldus, C.D.1    Tanner, S.M.2    Ruppert, A.S.3
  • 49
    • 45949110015 scopus 로고    scopus 로고
    • High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study
    • Langer C, Radmacher MD, Ruppert AS, et al: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-5379, 2008
    • (2008) Blood , vol.111 , pp. 5371-5379
    • Langer, C.1    Radmacher, M.D.2    Ruppert, A.S.3
  • 50
    • 67650312343 scopus 로고    scopus 로고
    • Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
    • Langer C, Marcucci G, Holland KB, et al: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 27:3198-3204, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3198-3204
    • Langer, C.1    Marcucci, G.2    Holland, K.B.3
  • 51
    • 50549095181 scopus 로고    scopus 로고
    • Let-7 microRNAs in development, stem cells and cancer
    • Büssing I, Slack FJ, Grosshans H: Let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 14:400-409, 2008
    • (2008) Trends Mol Med , vol.14 , pp. 400-409
    • Büssing, I.1    Slack, F.J.2    Grosshans, H.3
  • 52
    • 28344438648 scopus 로고    scopus 로고
    • A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis
    • Fazi F, Rosa A, Fatica A, et al: A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell 123:819-831, 2005
    • (2005) Cell , vol.123 , pp. 819-831
    • Fazi, F.1    Rosa, A.2    Fatica, A.3
  • 53
    • 47749117212 scopus 로고    scopus 로고
    • Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia
    • Dixon-McIver A, East P, Mein CA, et al: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3:e2141, 2008
    • (2008) PLoS One , vol.3
    • Dixon-McIver, A.1    East, P.2    Mein, C.A.3
  • 54
    • 84865763332 scopus 로고
    • Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    • Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
    • (1909) N Engl J Med 358 , vol.2008
    • Schlenk, R.F.1    Döhner, K.2    Krauter, J.3
  • 55
    • 2942667930 scopus 로고    scopus 로고
    • Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia
    • Osato M: Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23:4284-4296, 2004
    • (2004) Oncogene , vol.23 , pp. 4284-4296
    • Osato, M.1
  • 56
    • 70449429509 scopus 로고    scopus 로고
    • Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status
    • Silva FP, Swagemakers SM, Erpelinck-Verschueren C, et al: Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood 114:3001-3007, 2009
    • (2009) Blood , vol.114 , pp. 3001-3007
    • Silva, F.P.1    Swagemakers, S.M.2    Erpelinck-Verschueren, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.